Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit.
The drugmaker also hiked its sales and earnings forecast for 2024 beyond Wall Street’s expectations even as it hustles to boost manufacturing and catch up to surging demand for the drugs.
Lilly said it was still dealing with supply issues that also hampered the company in the fourth quarter. Company officials expect that to persist through this year, but they emphasized Tuesday that help was on the way.
They expect significant manufacturing increases to occur, starting in the back half of the year.
CEO David Ricks told analysts Tuesday that Lilly was undergoing “the most ambitious expansion plan in our company’s history.”
Indianapolis-based Eli Lilly and Co. recorded $517 million in sales from Zepbound, which received approval from U.S. regulators last November. Total Mounjaro sales more than tripled to $1.81 billion from $568 million in last year’s quarter.
G7 nations commit to phasing out coal by 2035 but give Japan some flexibility
Messi sidelined for Argentina friendlies with injury
Democrats seek to seize control of deadlocked Michigan House in special elections
Bayern in unrest ahead of Arsenal clash
Finnish hacker imprisoned for accessing thousands of psychotherapy records and demanding ransoms
Jiulong Peak: A paradise of nature, knowledge and prosperity
Shanghai Disney Resort launches Earth Month activities
Wanderlust will spark recovery
Finnish hacker imprisoned for accessing thousands of psychotherapy records and demanding ransoms
Dortmund face striker problem ahead of Atletico clash
US, Mexico drop bid to host 2027 World Cup
Chinese shuttlers into all five finals at Badminton Asia Championships